Table 1.
Demographics and genetic-molecular measures (Mean ± SD) NC.
| NC (n = 11) | FXTp- (n = 11) | FXTp+ (n = 11) | P | |
|---|---|---|---|---|
| Age | 63.7 ± 7.7 | 63.7 ± 9.2 | 62.2 ± 7.7 | 0.88 |
| Education (years) | 15.72 ± 1.85 | 14.55 ± 3.05 | 15.09 ± 2.88 | 0.58 |
| Females (N) | 5 | 5 | 5 | |
| Left-handed (N) | 1 | 1 | 1 | |
| FXTAS stage | – | 3.10 ± 0.88 | 3.27 ± 0.65 | 0.80# |
| CGG repeats | 32.43 ± 7.83 | 96.18 ± 33.57 | 84.75 ± 14.65 | 0.51# |
| FMR1 mRNA | 1.42 ± 0.38 | 2.99 ± 0.62 | 3.05 ± 0.52 | 0.98# |
| (n = 20) | (n = 6) | (n = 7) | (n = 7) | |
NC, normal controls; FXTp-, FXTAS patients without parkinsonism; FXTp+, FXTAS patients with parkinsonism. FXTAS disease stages were based on the functioning levels as defined in Jacquemont et al. (2003). #Indicates p-values from comparisons between two FXTAS subgroups.